Record PAT masks AI margin compression; polycarbonate platform de-risks cycles
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Buy
confidence 7/10
Grade B
Hit Q2 delivery on phenol; AI margin compression expected as new assets ramp—phasing in line with guidance
Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Record Q2 delivery (PAT +235% YoY, ₹3,091 Cr revenue) backed by phenol strength and new asset ramps; long-term polycarbonate platform + integrated value chains de-risk commodity cyclicality. Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.
₹3091 Cr
Revenue · +61.8% YoY₹398 Cr
Reported PAT · +234.9% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Achieved highest ever quarterly revenue and EBITDA
METQ2 revenue ₹3,091 Cr (best-ever Q2), consolidated EBITDA ₹643 Cr (+187% YoY)
Phenolics highest ever quarterly revenue
METPhenol segment ₹2,291 Cr (+72% YoY, +29% QoQ), confirmed as record
Advanced Intermediates buoyant Q1 demand, margins moderate in Q2
MISSQ2 revenue ₹811 Cr (flat QoQ), EBIT ₹49 Cr (down 27% QoQ from ₹67 Cr), margin 6%
Phenol 4 lakh tonne capacity sustained
METManagement: 'come close enough to 4 lakh tonnes plus or minus', constrained by propylene supply
MIBK/MIBC operational by Q2, acetophenone commissioned
METBoth commissioned Q2; MIBK/MIBC at 60% utilization, acetophenone ramp Q3 onwards
H2 FY27 AI margin recovery expected toward Q1 levels
METManagement guided Q3 EBIT % 'between Q1 and Q2, closer to Q1' (Q1: 11%, Q2: 6%)
Earnings quality
What changed since the last call
Phenol demand surge extends, now at "peak", not structural growth
NeutralQ1 call: strong domestic demand. Q2 call: 'geopolitical disruptions + supply tightness favorable, but not a super cycle.' Management reset expectations—peak cycle, not new normal.
Advanced Intermediates margin compression vs Q1 guidance
DowngradeQ1 implied recovery to 11%+ EBIT margin in Q2; instead Q2 delivered 6% margin. Root: 'lower capacity utilization' due to raw material cost volatility and demand moderation.
Polycarbonate timeline shifted from FY29 to FY30-31
DowngradeInvestor deck implied H2 FY28-29 polycarbonate entry; call confirms FY31 integration. Phenol/BPA commissioning in line, but polycarbonate resin plant delayed.
Capex profile: less FY27, more FY28-30
NeutralPrior: ₹3.2 Cr FY27 (of ₹11.5 Cr total). Now: ~₹800-900 Cr H2 FY27, ₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29. Total ₹11.7 Cr (flat), just re-phased.
MIBK/MIBC launched on-schedule, but ramp slower than hoped
NewCommissioned Q2 as promised, but at 60% utilization targeting 100%. Indicates market absorption or internal yield challenges in early run.
The Q&A
Analysts pressed on AI margin recovery timing, phenol cycle sustainability, and polycarbonate approvals. Management held firm on 14-15% AI EBIT target (steady-state, not imminent), acknowledged phenol cycle peak candidly, and confirmed FY31 polycarbonate. Q&A was detailed but revealed no major concessions.
AI capacity utilization — Nirav Jimudia, Anvil Wealth
AnsweredQ3 EBIT margin expected between Q1 and Q2 levels, closer to Q1 (~11%). New assets ramping gradually; full utilization realization by FY28-29.
Phenol competition dynamics — Archit Joshi, Nuvama
AnsweredIndia's 2 lakh tonne new capacity growth already absorbed. China participates selectively (when imports cheaper). Deepak's debottlenecking + scale moat insulate us. Pricing power holds.
Advanced Intermediates EBIT guidance — Sanjesh Jain, ICICI
Answered₹240-400 crore in absolute terms at steady-state with 14-15% EBIT margin. New assets contribute ₹250+ Cr incremental EBIT as utilization improves.
Phenol demand and imports — Arun Prasath, Avendus
AnsweredIndia's consumption growing 6-7% annually; demand resilient for chemicals, laminates, autos. China not participating selectively. India's SKU diversity (specialty-grade) commands premium. Wallet share expansion, not commodity dumping.
Polycarbonate approval timeline — Ankur Periwal, Axis
AnsweredApprovals are for compounds, not resins. Resins being imported for now. FY31 integrated plant ramp-up; FY32+ selling compounds to the market alongside resin supply.
Capex guidance multi-year — Abhijit Akella, Kotak
Answered₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr balance FY29-30. Total ₹11.7 Cr. Equity mostly done (~₹50 Cr left), debt funding main lever.
Volume vs price growth mix — Adiya Iyer, HDFC
PartialVolume roughly flat YoY (Q1 shutdown impact). Growth is price realization + procurement efficiency. Optimal run rate achieved; headroom available but not maxed out.
Acetone captive consumption — Rohit Nagraj, 360 ONE
AnsweredIntegrated approach: 60-65% consumed captively, balance sold externally. Full utilization dependent on market demand; we optimize for profitability, not volume maximization.
New specialty molecules R&D — Rishabh Tripathi, Multi Dimensional
AnsweredCDMO opportunities being explored; R&D from kilo-lab to pilot scale in progress. Early-stage, not material revenue yet. Personal care and specialty laminates high-value focus areas.
China competitive pressure — Vansh Gupta, Prescient
AnsweredNo significant impact. Propylene/ammonia shortage benefits Indian makers. Integrated approach + multi-SKU moat shields us. India's growth story resilient; China not dominating here.
Guidance
No explicit FY27 revenue target; H1 ₹5,682 Cr suggests ₹11-12 Cr+ FY27
MediumPhenol sustains 4 LT; AI recovery in H2 FY27 drives incremental. Propylene supply constrains phenol upside.
Phenol: Sustain 20%+ EBIT margin; commodity cycle risk if feedstock inflation
HighQ2 demonstrated 22% phenol EBIT margin at peak cycle. Management realistic: 'not a super cycle,' but sustained at current levels likely H2 FY27.
AI EBIT margin: Recovery from 6% Q2 to 11% (Q1-like) in Q3; target 14-15% FY28-29
MediumDependent on new asset utilization ramp (nitration, etc.) and market absorption. Phased ramp expected; full steady-state ₹240-400 Cr absolute EBIT.
₹2.2-2.4 Cr FY28, ₹2.5 Cr FY28-29, ₹2.5-3 Cr FY29-30, total ₹11.7 Cr over 4 years
HighEquity funding ~done (₹50 Cr left); debt main lever (60:40 debt:equity agreed). Polycarbonate ~60% of capex; rest AI expansion & debottlenecking.
Risks the call surfaced
Phenol cycle peak
HighPhenol at 'peak' driven by geopolitical supply disruptions + freight tightness. Management explicit: 'not a super cycle.' Normalization risks 5-10% margin compression.
AI segment margin recovery timing
HighAI EBIT fell 27% QoQ despite revenue +38% YoY, margin only 6% vs target 14-15%. Recovery dependent on new asset full-load utilization (nitration, etc.) and market absorption. Phased ramp could extend recovery past FY28.
Polycarbonate execution & approval cycle
HighFY31 polycarbonate plant entry is 18 months away; requires feedstock PDH plant commissioning, resin pilot qualification at scale, and customer approvals across 500+ grades. Delay or cost overrun likely given specialty complexity.
Propylene feedstock supply
MediumPhenol ramp constrained by propylene availability; management notes 'disturbance with regards to propylene availability' in recent months. Non-traditional sourcing required at higher cost; limits margin expansion.
New asset underutilization
MediumMIBK/MIBC running at 60% utilization (vs target 100%+); acetophenone just launched (Q3 ramp uncertain). If market absorption slower than guided, AI margin recovery delayed; capex returns compressed.
Macro / geopolitical volatility
MediumStrong Q2 driven by supply-chain disruptions (freight, import tightness, China anti-involution). If geopolitical normalizes (freight costs fall, imports resume), tailwind reverses. Phenol cycle compressed; AI margin pressure.
Management
Score 8/10. Structured, quantified, candid on cycles (phenol peak acknowledgment) and execution risks (propylene supply, polycarbonate delay). NDA shields held where needed (customer names), but specifics on EBIT targets and capex provided. Hit Q2 delivery on phenolics (record revenue/EBIT); AI margin compression expected but timeline slippage on polycarbonate (FY29→FY30-31). Capex on track; equity funding mostly done.
1 · Q3 FY27
AI EBIT margin recovery toward 11% (Q1 level); acetophenone ramp-up
2 · H2 FY27
Phenol 4 LT sustained amid propylene supply tightness; MIBK/MIBC move toward 100% utilization
3 · H2 FY27
REACH registration approval for MIBK/MIBC opens EU export markets
Key risk: phenol cycle at peak, AI margin recovery timing uncertain, propylene supply constraints.
Informational and educational content only. Not investment advice.